小野薬品工業(株)【4528】の掲示板 2018/04/12〜2018/04/17

>>591

（好材料）
１） ameyujyu さんのコメント。ＣＭ０７８　　　　　　　　　　　　　　　　　　　
(BMY) today announced results from the pivotal, randomized Phase 3 CheckMate -078 trial
Findings will be presented on Monday, April 16 from 4:05-4:20 PM CDT during the Updates in Immuno-Oncology Trials session at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago (Abstract #CT114).
２）Apr 13, 2018 4:51 p.m. ET
Bristol-Myers Squibb Co. BMY, -0.32% announced they'll use Illumina's next-generation sequencing technology to develop cancer drugs at Bristol-Myers. The companies said they will use the Illumina TruSight Oncology 500 test to find genetic biomarkers to target in the development of cancer drugs. Bristol-Myers shares advanced 0.6% after hours, following a 0.3% decline to close at $58.65 in the regular session.


来週の月曜日（１６日）ＡＡＣＲから株価がどう動くかに注目ですね。

>>591

>Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study

＞On 16th, Monday, prospective most bullish MRK & bearish BMS　（月曜に開催されるＡＡＣＲで最も期待の高いのがメルクで弱気なのがＢＭＳということです）

マーケットは予想通りの反応を示しました（　残念ですが。。。）
株価は正直です。

小野のＡＤＲはそれでも今のところ８．４１ドル（３％の下げ）といったところです。